Novel TGF-β1 Inhibitor Linavonkibart Shows Promise in Overcoming Immune Checkpoint Resistance
Key Insights
Linavonkibart, a first-in-class selective TGF-β1 (search) inhibitor, demonstrated a manageable safety profile and encouraging antitumor activity when combined with pembrolizumab in heavily pretreated patients with immune checkpoint blockade-resistant solid tumors.
The Phase I DRAGON trial showed a 20% objective response rate in clear cell renal cell carcinoma (search) patients, with responses also observed in melanoma (search), head and neck squamous cell cancer (search), and urothelial cancer (search) despite prior anti-PD-1 (search) therapy resistance.
Biomarker analyses revealed that patients with elevated baseline CD8 (search)+ T cells, regulatory T cells, or TGF-β1 (search) expression had improved response rates, suggesting a potential patient selection strategy for future treatment approaches.
The first-in-human Phase I DRAGON trial of linavonkibart, a novel monoclonal antibody targeting transforming growth factor-beta 1 (TGF-β1 (search)), has demonstrated promising antitumor activity and a manageable safety profile in patients with immune checkpoint inhibitor-resistant advanced solid tumors. The study, led by researchers at The University of Texas MD Anderson Cancer Center and published in Nature Medicine, represents a potential breakthrough in overcoming resistance to anti-PD-1 (search) therapies.
Addressing a Critical Unmet Need
Despite the revolutionary impact of immune checkpoint inhibitors, primary and secondary resistance remains a substantial challenge across multiple cancer types. Research has identified TGF-β1 (search) signaling as a dominant contributor to this resistance, making it an attractive therapeutic target. However, previous attempts to develop TGF-β pathway inhibitors have failed due to dose-limiting toxicities associated with blocking all three TGF-β isoforms.
"This is a very exciting trial because we've been trying to effectively target this protein, called transforming growth factor-beta 1, for a long time," said Timothy Yap, M.B.B.S., Ph.D., professor of Investigational Cancer Therapeutics at MD Anderson and lead investigator of the study. "We've known that it helps tumors evade the immune system and develop resistance to immunotherapies but, until now, attempts to target it have failed."
Novel Selective Targeting Strategy
Linavonkibart represents a first-in-class approach, designed to selectively target the latent form of TGF-β1 (search) while preserving TGF-β2 and TGF-β3 signaling needed for normal physiological functions. This selective inhibition strategy aims to minimize the dose-limiting toxicities that have plagued previous pan-TGF-β inhibitors.
The DRAGON trial enrolled 112 patients across three treatment arms: single-agent linavonkibart (19 patients), combination dose escalation with pembrolizumab (15 patients), and combination dose expansion (78 patients). All patients had heavily pretreated, advanced solid tumors with documented resistance to prior anti-PD-1 (search) therapy.
Encouraging Safety Profile
The safety analysis revealed no dose-limiting toxicities or grade 4 or 5 treatment-related adverse events in either dose escalation cohort. In the expansion cohort of 78 patients, 73.1% experienced at least one treatment-related adverse event of any grade, with 32.1% experiencing grade 3 or higher events. The most common adverse events were rash (33.3%), pruritus (28.2%), fatigue (21.8%), and diarrhea (16.7%).
Importantly, no patients developed cytokine release syndrome, and the safety profile of linavonkibart combined with pembrolizumab was generally consistent with pembrolizumab monotherapy. Only 19.2% of patients discontinued treatment due to linavonkibart-related or anti-PD-1 (search)-related adverse events.
Clinical Activity Across Multiple Tumor Types
In the dose expansion cohorts, confirmed objective response rates were observed across several cancer types: 20.0% in clear cell renal cell carcinoma (search) (ccRCC), 18.2% in melanoma (search), 9.1% in head and neck squamous cell cancer (search), and 9.1% in urothelial cancer (search). One patient achieved a complete response in the ccRCC cohort.
The median duration of response was particularly encouraging, ranging from 5.6 months in melanoma (search) to 16.0 months in head and neck cancer. For responding patients, the median duration of treatment with linavonkibart and pembrolizumab was 13.8 months, compared to 4.5 months with their most recent prior anti-PD-1 (search) therapy.
Biomarker-Driven Patient Selection
Comprehensive biomarker analyses provided insights into the mechanism of action and potential patient selection strategies. In ccRCC patients with available tumor biopsies, those with elevated baseline CD8 (search)+ T cells, regulatory T cells, or TGF-β1 (search) expression showed improved response rates compared to the overall population.
Specifically, the objective response rate increased from 20.0% for all ccRCC patients to 33.3% for those with elevated baseline CD8 (search)+ T cell infiltration and to 57.1% for those with elevated regulatory T cells. These findings suggest that baseline biomarker levels could guide patient selection for optimal treatment outcomes.
Mechanism of Action Insights
Immunohistochemistry analyses confirmed that linavonkibart and pembrolizumab treatment increased CD8 (search)+ T cell infiltration and activation within the tumor compartment compared to baseline. The combination therapy also reduced the ratio of immunosuppressive regulatory T cells to active CD8+ T cells, particularly in responding patients.
Additionally, circulating granulocytic myeloid-derived suppressor cells were decreased in most responding patients, supporting the hypothesis that linavonkibart helps convert the tumor microenvironment to a more proinflammatory state.
Future Directions
The encouraging results from this heavily pretreated patient population suggest even greater potential in earlier treatment settings. "It's notable that our Phase I trial involved a very heavily pretreated population with a prognosis of just over three months," Yap noted. "We believe that this linavonkibart combination will be even more effective when given in earlier treatment settings, before significant resistance to immunotherapy has developed."
The study investigators are currently developing a Phase II trial to further evaluate linavonkibart in combination with additional antitumor agents alongside immune checkpoint inhibitors. The biomarker findings also provide a foundation for developing patient selection strategies to optimize treatment outcomes.
This first-in-human study validates the selective latent TGF-β1 (search)-targeting strategy and provides proof of concept for overcoming immune checkpoint inhibitor resistance through this novel mechanism. The encouraging therapeutic index and benefit-risk profile support continued clinical development of linavonkibart as a potential solution to one of the most significant challenges in cancer immunotherapy.